Antibe Therapeutics - Blockbusterpotential - 500 Beiträge pro Seite
eröffnet am 29.06.18 22:57:10 von
neuester Beitrag 10.01.21 12:44:30 von
neuester Beitrag 10.01.21 12:44:30 von
Beiträge: 33
ID: 1.283.539
ID: 1.283.539
Aufrufe heute: 0
Gesamt: 3.888
Gesamt: 3.888
Aktive User: 0
ISIN: CA0370255097 · WKN: A2QJPN · Symbol: ATE
0,0100
CAD
0,00 %
0,0000 CAD
Letzter Kurs 13.05.24 Toronto
Neuigkeiten
10.04.24 · Business Wire (engl.)  |
09.04.24 · Business Wire (engl.) |
01.04.24 · Business Wire (engl.) |
20.03.24 · Business Wire (engl.) |
07.03.24 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9998 | +169,42 | |
| 1,0000 | +33,33 | |
| 0,5500 | +22,22 | |
| 15,348 | +19,53 | |
| 1,6500 | +17,86 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6.059,00 | -15,16 | |
| 4,5001 | -17,43 | |
| 5,2500 | -19,23 | |
| 5,2300 | -20,64 | |
| 0,7800 | -29,73 |
Feedback
Antibe Therapeutics
Antibes Meilenstein News von März 2018
die den Wert auf ein Intradayhigh von 0,79 C$ katapultierte
mit anschließender Konsolidierung
die seit Anfang Mai seitlich verläuft
Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346
TORONTO
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal (“GI”) safety study. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the USA. Subjects on ATB-346 exhibited an ulceration rate of 2.5% versus an ulceration rate of 42.1% for subjects on naproxen at the end of the 2-week treatment period, with a very high degree of statistical significance (p<0.001). ATB-346 was also safe and well tolerated.
Antibe’s Chief Scientific Officer, John Wallace, commented, “The successful outcome of this study is the culmination of 15+ years of scientific research, and validates Antibe’s hydrogen sulfide-releasing technology. Gastrointestinal safety has been a major global concern with NSAIDs for decades and we now have clinical data unequivocally demonstrating a solution to this unmet and serious medical problem.”
https://web.tmxmoney.com/article.php?newsid=8671532321449129…
Jeder Aktienhandel ist mit Risiken verbunden und selbstverständlich völlig eigenverantwortlich DYODD
Antibes Meilenstein News von März 2018
die den Wert auf ein Intradayhigh von 0,79 C$ katapultierte
mit anschließender Konsolidierung
die seit Anfang Mai seitlich verläuft
Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346
TORONTO
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal (“GI”) safety study. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the USA. Subjects on ATB-346 exhibited an ulceration rate of 2.5% versus an ulceration rate of 42.1% for subjects on naproxen at the end of the 2-week treatment period, with a very high degree of statistical significance (p<0.001). ATB-346 was also safe and well tolerated.
Antibe’s Chief Scientific Officer, John Wallace, commented, “The successful outcome of this study is the culmination of 15+ years of scientific research, and validates Antibe’s hydrogen sulfide-releasing technology. Gastrointestinal safety has been a major global concern with NSAIDs for decades and we now have clinical data unequivocally demonstrating a solution to this unmet and serious medical problem.”
https://web.tmxmoney.com/article.php?newsid=8671532321449129…
Jeder Aktienhandel ist mit Risiken verbunden und selbstverständlich völlig eigenverantwortlich DYODD
Antibe Therapeutics (“Antibe”) is a public biotech company with a drug platform of game-changing therapeutics in pain and inflammation. Its lead drug, ATB-346, recently showed unequivocal superiority to naproxen in GI safety, and its combined pipeline is targeting a global market opportunity in excess of $20 billion. Antibe’s commercial division in regenerative medicine is on a growth trajectory in the dental biologics market.
Pursuing Blockbuster Drug Opportunities in Pain & Inflammation
Antibe Therapeutics is pursuing a major advance in the safe and non-addictive treatment of pain and inflammation. Our drugs are designed to prevent the widespread and serious gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs (“NSAIDs”), today’s most widely used medicines for the relief of pain. The NSAID class of drugs includes prescription and over-the-counter (“OTC”) brands such as naproxen (Aleve), celecoxib (Celebrex), ibuprofen (Advil), and Aspirin.
Global NSAID sales exceed $11 billion annually, a significant market opportunity that could potentially be disrupted by Antibe’s H2S technology.
Regenerative Medicine Division Poised for Growth
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products for oral and maxillofacial surgery. Since its inception in 1997, Citagenix has become an important source of knowledge and experience in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. More recently, Citagenix initiated a strategic growth initiative in the United States, the largest global market for oral regenerative medicine.
Antibe’s subsidiary, Citagenix, is leveraging its market leading position in Canada to pursue a growth strategy in the dental biologics market.
http://www.antibethera.com
Pursuing Blockbuster Drug Opportunities in Pain & Inflammation
Antibe Therapeutics is pursuing a major advance in the safe and non-addictive treatment of pain and inflammation. Our drugs are designed to prevent the widespread and serious gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs (“NSAIDs”), today’s most widely used medicines for the relief of pain. The NSAID class of drugs includes prescription and over-the-counter (“OTC”) brands such as naproxen (Aleve), celecoxib (Celebrex), ibuprofen (Advil), and Aspirin.
Global NSAID sales exceed $11 billion annually, a significant market opportunity that could potentially be disrupted by Antibe’s H2S technology.
Regenerative Medicine Division Poised for Growth
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products for oral and maxillofacial surgery. Since its inception in 1997, Citagenix has become an important source of knowledge and experience in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. More recently, Citagenix initiated a strategic growth initiative in the United States, the largest global market for oral regenerative medicine.
Antibe’s subsidiary, Citagenix, is leveraging its market leading position in Canada to pursue a growth strategy in the dental biologics market.
http://www.antibethera.com
Antibe Therapeutics Announces CEO Letter to Shareholders
APRIL 26, 2018
The recent success of our lead drug, ATB-346, in its Phase 2B gastrointestinal (“GI”) safety clinical study was a significant milestone for Antibe and represented a major inflection point in our value. Furthermore, we are now one clinical study away from the strategic monetization of our drug platform for the major markets. With such an important and exciting time ahead of us, we thought this would be an ideal opportunity to communicate our strategy for the next year and beyond.
Nearly ten years ago, Antibe was formed to develop safer medicines for pain and inflammation by leveraging our novel hydrogen sulfide (“H2S”) technology. Over this period, our strategy to maximize value for shareholders has remained consistent: advance our drug candidates to Phase 2 proof-of-concept data and secure high-value partnerships for the large pharmaceutical markets. Fast forward to 2018: we now have unequivocal validation of our H2S platform, and are well-positioned to conclude a series of transformational partnerships over the next 12-18 months..............
Upcoming Phase 2 Effectiveness Study Designed to Validate Efficacy of ATB-346
With human GI safety for ATB-346 now firmly established, our next clinical objective is to validate its effectiveness at reducing pain in osteoarthritis (“OA”) patients.............
............. Although ATB-352 and ATB-340 are earlier stage, both individually represent blockbuster drug opportunities and have been considerably de-risked by the latest validation of our H2S technology. We remain particularly excited about the potential of ATB-352, a non-addictive, potent analgesic for acute pain that directly addresses the global opioid epidemic, a crisis that the world is struggling to contain.............
http://www.antibethera.com/2018/04/26/antibe-therapeutics-an…
APRIL 26, 2018
The recent success of our lead drug, ATB-346, in its Phase 2B gastrointestinal (“GI”) safety clinical study was a significant milestone for Antibe and represented a major inflection point in our value. Furthermore, we are now one clinical study away from the strategic monetization of our drug platform for the major markets. With such an important and exciting time ahead of us, we thought this would be an ideal opportunity to communicate our strategy for the next year and beyond.
Nearly ten years ago, Antibe was formed to develop safer medicines for pain and inflammation by leveraging our novel hydrogen sulfide (“H2S”) technology. Over this period, our strategy to maximize value for shareholders has remained consistent: advance our drug candidates to Phase 2 proof-of-concept data and secure high-value partnerships for the large pharmaceutical markets. Fast forward to 2018: we now have unequivocal validation of our H2S platform, and are well-positioned to conclude a series of transformational partnerships over the next 12-18 months..............
Upcoming Phase 2 Effectiveness Study Designed to Validate Efficacy of ATB-346
With human GI safety for ATB-346 now firmly established, our next clinical objective is to validate its effectiveness at reducing pain in osteoarthritis (“OA”) patients.............
............. Although ATB-352 and ATB-340 are earlier stage, both individually represent blockbuster drug opportunities and have been considerably de-risked by the latest validation of our H2S technology. We remain particularly excited about the potential of ATB-352, a non-addictive, potent analgesic for acute pain that directly addresses the global opioid epidemic, a crisis that the world is struggling to contain.............
http://www.antibethera.com/2018/04/26/antibe-therapeutics-an…
Antibe Therapeutics - Top Midas Letter Watch List
https://midasletter.com/2018/06/cannaroyalty-antibe-therapeu…
https://midasletter.com/2018/06/cannaroyalty-antibe-therapeu…
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
Trading Spotlight
Antibe Therapeutics
Working towards a GI-safe NSAID drug
14 June 2018 | Antibe Therapeutics, Pharma & biotech, Quickview
https://www.edisoninvestmentresearch.com/research/report/ant…
Working towards a GI-safe NSAID drug
14 June 2018 | Antibe Therapeutics, Pharma & biotech, Quickview
https://www.edisoninvestmentresearch.com/research/report/ant…
Antibe Therapeutics mit interessantem Langfristchart
Letzte NR war im August:
Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346
http://www.antibethera.com/2019/08/27/antibe-therapeutics-pr…
About ATB-346
ATB-346 is a hydrogen sulfide-releasing derivative of naproxen. Nonsteroidal anti-inflammatory drugs (“NSAIDs”) are the most commonly used therapy for osteoarthritis, but their use is associated with a high incidence of gastrointestinal ulceration and bleeding. NSAIDs are also widely used in conditions such as rheumatoid arthritis, ankylosing spondylitis, gout, and general pain reduction, with a similarly high rate of gastrointestinal ulceration and bleeding. It is well-accepted that patients with these conditions would benefit greatly from an effective, non-addictive, GI-sparing anti-inflammatory/analgesic agent such as ATB-346.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a gastrointestinal-safe derivative of aspirin. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace.
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
Letzte NR war im August:
Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346
http://www.antibethera.com/2019/08/27/antibe-therapeutics-pr…
About ATB-346
ATB-346 is a hydrogen sulfide-releasing derivative of naproxen. Nonsteroidal anti-inflammatory drugs (“NSAIDs”) are the most commonly used therapy for osteoarthritis, but their use is associated with a high incidence of gastrointestinal ulceration and bleeding. NSAIDs are also widely used in conditions such as rheumatoid arthritis, ankylosing spondylitis, gout, and general pain reduction, with a similarly high rate of gastrointestinal ulceration and bleeding. It is well-accepted that patients with these conditions would benefit greatly from an effective, non-addictive, GI-sparing anti-inflammatory/analgesic agent such as ATB-346.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a gastrointestinal-safe derivative of aspirin. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace.
Bin dabei
Antibe Therapeutics läuft bisher richtig gut in 2020
ANTIBE THERAPEUTICS EXPANDS EXECUTIVE TEAM IN PREPARATION FOR LARGE MARKET PARTNERING
https://antibethera.com/news/antibe-therapeutics-expands-exe…
ANTIBE THERAPEUTICS EXPANDS EXECUTIVE TEAM IN PREPARATION FOR LARGE MARKET PARTNERING
https://antibethera.com/news/antibe-therapeutics-expands-exe…
Antibe Therapeutics
hat sich bemerkenswert gehalten
während des Crashs
auf den Support bei 0,40 konsolidiert
und dann rasch wieder bis zur Widerstandszone
um die 0,60 CAD angestiegen
Das könnte an der Ankündigung aus der
letzten NR liegen
die "top-line results within six weeks"
in Aussicht stellte
ANTIBE THERAPEUTICS ANNOUNCES ENROLLMENT OF LAST PATIENT IN PHASE 2B DOSE-RANGING, EFFICACY STUDY OF LEAD DRUG, ATB-346
https://antibethera.com/news/antibe-therapeutics-announces-e…
hat sich bemerkenswert gehalten
während des Crashs
auf den Support bei 0,40 konsolidiert
und dann rasch wieder bis zur Widerstandszone
um die 0,60 CAD angestiegen
Das könnte an der Ankündigung aus der
letzten NR liegen
die "top-line results within six weeks"
in Aussicht stellte
ANTIBE THERAPEUTICS ANNOUNCES ENROLLMENT OF LAST PATIENT IN PHASE 2B DOSE-RANGING, EFFICACY STUDY OF LEAD DRUG, ATB-346
https://antibethera.com/news/antibe-therapeutics-announces-e…
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
Antibe Therapeutics
House 18 Echelon Wealth scheint positive Ergebnisse zu erwarten
sie haben diese Woche wie es scheint 1 Million Stücke eingesammelt
House 18 Echelon Wealth scheint positive Ergebnisse zu erwarten
sie haben diese Woche wie es scheint 1 Million Stücke eingesammelt
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
Antibe CEO Dan Legault
Pain Relief And No Ulcers? 'Magic Aleve' In Clinical Trials
American Council on Science and Health
By Josh Bloom
"Antibe is trying to develop a pro-drug (2) of naproxen called ATB-346, which can eliminate GI side effects by having the drug bypass the stomach before releasing the naproxen. But ATB-346 takes it a step further. It was designed to also release small amounts of hydrogen sulfide, the poisonous gas from rotten eggs, upon decomposition. Best yet, the hydrogen sulfide isn't just coming along for the ride; it can also act as an antiinflammatory agent. Two drugs for the price of one. Amazing."
"This could be huge. Seriously."
"Keep your arthritic fingers crossed that I'm right."
https://www.acsh.org/news/2020/03/01/huge-advance-pain-manag…
Die IIb Resultate werden zeitnahe erwartet
das wird die Nagelprobe für Antibe
American Council on Science and Health
By Josh Bloom
"Antibe is trying to develop a pro-drug (2) of naproxen called ATB-346, which can eliminate GI side effects by having the drug bypass the stomach before releasing the naproxen. But ATB-346 takes it a step further. It was designed to also release small amounts of hydrogen sulfide, the poisonous gas from rotten eggs, upon decomposition. Best yet, the hydrogen sulfide isn't just coming along for the ride; it can also act as an antiinflammatory agent. Two drugs for the price of one. Amazing."
"This could be huge. Seriously."
"Keep your arthritic fingers crossed that I'm right."
https://www.acsh.org/news/2020/03/01/huge-advance-pain-manag…
Die IIb Resultate werden zeitnahe erwartet
das wird die Nagelprobe für Antibe
ANTIBE THERAPEUTICS UPDATES TIMING FOR TOP-LINE RESULTS FROM COMPLETED PHASE 2B DOSE-RANGING, EFFICACY STUDY
TORONTO, CANADA — (May 4, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today provides an update on the timing of top-line results for the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. Involving 360 patients across 40 clinical sites, this study is one of the largest ever undertaken in Canada. The Company is pleased to report that its clinical research organization (“CRO”), Veristat, was able to complete the trial and capture all patient data without compromising the size and integrity of the study. However, ongoing hospital restrictions, clinic closures and complexities arising from remote working constraints have slowed Veristat’s data collection, validation and analysis beyond the timeframe envisioned last month. As a result of these new updates from its CRO, the Company anticipates the release of top-line results within six weeks. Antibe confirms that it will remain blinded until Veristat releases these results to the Company.
https://antibethera.com/news/antibe-therapeutics-updates-tim…
Die Verzögerung dürfte die Trader erst einmal rausgespült
und so manchen stop loss ausgelöst haben
Bisher hat sich der Wert aber dafür bemerkenswert stark behauptet
TORONTO, CANADA — (May 4, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today provides an update on the timing of top-line results for the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. Involving 360 patients across 40 clinical sites, this study is one of the largest ever undertaken in Canada. The Company is pleased to report that its clinical research organization (“CRO”), Veristat, was able to complete the trial and capture all patient data without compromising the size and integrity of the study. However, ongoing hospital restrictions, clinic closures and complexities arising from remote working constraints have slowed Veristat’s data collection, validation and analysis beyond the timeframe envisioned last month. As a result of these new updates from its CRO, the Company anticipates the release of top-line results within six weeks. Antibe confirms that it will remain blinded until Veristat releases these results to the Company.
https://antibethera.com/news/antibe-therapeutics-updates-tim…
Die Verzögerung dürfte die Trader erst einmal rausgespült
und so manchen stop loss ausgelöst haben
Bisher hat sich der Wert aber dafür bemerkenswert stark behauptet
Antibe Therapeutics - schon interessant
wenn eine Company noch vor Bekanntwerden der Ergebnisse
den Top-Spezialisten anheuert
Antibe Therapeutics Announces the Hiring of Chief Medical Officer
........He then joined the US Food and Drug Administration (“FDA”) as a Medical Review Officer for anti-inflammatory and analgesic drugs, subsequently being recruited by Abbott Laboratories as Global Medical Director. Over the succeeding years, Dr. Stauffer led clinical operations, regulatory and medical affairs teams at Alpharma and Ikaria, each of which was acquired in $1.6 billion cash transactions......
https://business.financialpost.com/pmn/press-releases-pmn/bu…
wenn eine Company noch vor Bekanntwerden der Ergebnisse
den Top-Spezialisten anheuert
Antibe Therapeutics Announces the Hiring of Chief Medical Officer
........He then joined the US Food and Drug Administration (“FDA”) as a Medical Review Officer for anti-inflammatory and analgesic drugs, subsequently being recruited by Abbott Laboratories as Global Medical Director. Over the succeeding years, Dr. Stauffer led clinical operations, regulatory and medical affairs teams at Alpharma and Ikaria, each of which was acquired in $1.6 billion cash transactions......
https://business.financialpost.com/pmn/press-releases-pmn/bu…
Antibe Therapeutics nähert sich wieder dem All-time High (0,85 CAD)
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346
https://ceo.ca/@businesswire/antibe-therapeutics-announces-p…
https://ceo.ca/@businesswire/antibe-therapeutics-announces-p…
Antwort auf Beitrag Nr.: 63.861.998 von HeinzBork am 01.06.20 14:41:20Moderater Start, hätte ich höher eingeschätzt 😇
Nun ja, kann ja keiner der Anleger was dafür, dass sie das gigantische Ereignis überlesen haben, was aus der Studie folgen wird. Schön blöd, aber das ist d i e Gelegenheit nachzukaufen.
ATE wird Blockbuster, und da lehne ich micht weit aus dem Fenster
https://stockhouse.com/companies/bullboard?symbol=v.ate&post…
June 1, 2020 - the Death of NSAIDS - proof of concept confirmed.
ATE wird Blockbuster, und da lehne ich micht weit aus dem Fenster
https://stockhouse.com/companies/bullboard?symbol=v.ate&post…
June 1, 2020 - the Death of NSAIDS - proof of concept confirmed.
Antwort auf Beitrag Nr.: 63.867.119 von HeinzBork am 02.06.20 09:09:18ANTIBE THERAPEUTICS TO HOST CONFERENCE CALL TO DISCUSS POSITIVE RESULTS OF PHASE 2B DOSE-RANGING, EFFICACY STUDY FOR ATB-346
https://www.stockwatch.com/News/Item?bid=Z-C%3aATE-2916143&s…
Vielleicht kommuniziert das Management dann ja geschickter als in der NR
ansonsten wäre auch nach unten noch Spielraum
Wer das Top gestern gekauft und heute am Low verkaufte
hat in 2 Tagen seinen halben Einsatz verspielt
Timing mit Chart so wichtig
der Venture kann sonst brutal sein
Die Shorts dürften ihren Spaß gehabt und sollten eigentlich jetzt größtenteils gecovert haben
und die Swing Trader warteten wohl in der möglichen Kaufzone
JMHO
https://www.stockwatch.com/News/Item?bid=Z-C%3aATE-2916143&s…
Vielleicht kommuniziert das Management dann ja geschickter als in der NR
ansonsten wäre auch nach unten noch Spielraum
Wer das Top gestern gekauft und heute am Low verkaufte
hat in 2 Tagen seinen halben Einsatz verspielt
Timing mit Chart so wichtig
der Venture kann sonst brutal sein
Die Shorts dürften ihren Spaß gehabt und sollten eigentlich jetzt größtenteils gecovert haben
und die Swing Trader warteten wohl in der möglichen Kaufzone
JMHO
Antwort auf Beitrag Nr.: 63.877.238 von Ti-el am 02.06.20 22:53:27Antibe Therapeutics is undervalued, Echelon analyst Loe says
3 hours ago
June 2, 2020
https://www.cantechletter.com/2020/06/antibe-therapeutics-is…
3 hours ago
June 2, 2020
https://www.cantechletter.com/2020/06/antibe-therapeutics-is…
Eventueller RS 1:5 oder 1:10 für mögliches Nasdaq-Listing
Moin!
Ist ja ruhig hier ; ) Dabei passiert hier gerade ne Menge...
https://ceo.ca/@businesswire/antibe-therapeutics-engages-ste…
Ist ja ruhig hier ; ) Dabei passiert hier gerade ne Menge...
https://ceo.ca/@businesswire/antibe-therapeutics-engages-ste…
Auch wenn es momentan niemanden zu interessieren scheint, stelle ich die Infos hier mal weiterhin rein : )
https://ca.proactiveinvestors.com/companies/news/926500/anti…
https://ca.proactiveinvestors.com/companies/news/926500/anti…
Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing
https://ceo.ca/@businesswire/antibe-therapeutics-to-complete…Das lässt vermuten, da kommt was Grosses auf uns zu
Gesundes neues Jahr noch,
ist die Konsolidierung der Aktien abgeschlossen???
Sollte ja eigentlich anfang Dezember erfolgen.
Gibt es da schon Infos??
ist die Konsolidierung der Aktien abgeschlossen???
Sollte ja eigentlich anfang Dezember erfolgen.
Gibt es da schon Infos??
Antwort auf Beitrag Nr.: 66.369.389 von Wertvoll01 am 10.01.21 11:27:06Ist doch schon längst erfolgt, falls Du die Aktie hast, müsstest Du gemerkt haben, daß Dein Vestand sich auf 10% verringert hat.
Der Kurs ist ja auch um 10x "gestiegen".
Der Kurs ist ja auch um 10x "gestiegen".
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +4,55 | |
| +11,76 | |
| -5,41 | |
| -5,88 | |
| +3,09 | |
| +0,54 | |
| 0,00 | |
| 0,00 | |
| 0,00 | |
| -1,43 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 160 | ||
| 86 | ||
| 77 | ||
| 70 | ||
| 66 | ||
| 54 | ||
| 45 | ||
| 45 | ||
| 37 | ||
| 36 |
